219 results about "Brucella" patented technology

A sheep single nucleotide polymorphism (SNP) molecular marker and use thereof in detecting resistance to brucellosis in sheep are provided, relating to the technical field of molecular marker-assisted breeding. A sheep SNP molecular marker is provided, where the sheep SNP molecular marker is associated with resistance to brucellosis in sheep, and has a nucleotide sequence shown in SEQ ID NO: 1 in which a T / C polymorphism is located at 101st bp. The sheep SNP molecular marker can accurately detect a resistance level of sheep to the brucellosis, and is used for the selection of brucellosis-resistant sheep as well as molecular marker-assisted breeding of the resistance to brucellosis in sheep. The sheep SNP molecular marker effectively improves a breeding efficiency of sheep with brucellosis resistance.

The invention discloses efficient carbon sequestration Brucella from an oil-containing solid waste residue source and application of the efficient carbon sequestration Brucella. The Brucella is Brucella sp A54-5 with the preservation number of CCTCC (China Center for Type Culture Collection) NO: M20241650. The Brucella is obtained through ARTP mutagenesis and screening by taking Brucella Brucella sp A54 separated from oil-containing solid waste residues of an oil field as a starting strain, has excellent characteristics of reducing pollution and sequestration carbon and relatively strong stress resistance, and has the advantages of deep recycling (soil transformation) of the oil-containing solid waste residues, improvement of the carbon sequestration capacity of petroleum-contaminated soil and improvement of the oil-containing solid waste residues. The method has a wide application prospect in the fields of petroleum-polluted soil remediation and the like, and has great significance in pollution reduction and convergence increase in petroleum and petrochemical industries under the background of supporting double carbon.

The invention relates to the technical field of space-time prediction, in particular to a brucellosis space-time prediction method and system based on artificial intelligence, and the method comprises the following steps: obtaining case information, calculating an incidence relation, extracting a path sequence, screening a trend direction, and matching a new case to generate prediction data. According to the method, continuous identification of a propagation path is realized by constructing a propagation incidence relation between cases and introducing a spatial directivity index, a non-trend propagation process is screened out through an angle average value and a variance, spatial consistency of path screening is enhanced, and through joint matching of spatio-temporal characteristics of newly-added cases and an existing propagation trend, the propagation path screening efficiency is improved. The sensitivity of prediction to the trend attribution of a new case is improved, the spatial directivity of a potential disease area is enhanced through reverse projection of a trend path and area positioning drop point frequency analysis, and through linkage processing of multi-level path extraction, trend judgment and area coding, the probability of occurrence of the new case is lowered. And the capturing capability of the prediction data on the propagation and evolution characteristics of the brucellosis is improved.

The invention discloses a Brucella with antibacterial activity and application of the Brucella. The invention discloses Burkholderia sp.HNIV0701, and the preservation number of the Burkholderia sp.HNIV0701 is GDMCC No: 66007. The Burkholderia sp.HNIV0701 disclosed by the invention has a stable, efficient and broad-spectrum antibacterial property, has an inhibition effect on a plurality of plant pathogenic bacteria such as Botryosphaeria dothidea, Phytophthora nicotianae, Fusarium solani, Alternaria alternata, Thanatepora cucurbitae, Ralstonia solanacearum and the like, and also can be used for inhibiting Staphylococcus aureus and / or Listeria monocytogenes, so that the Burkholderia sp.HNIV0701 can be used for inhibiting a plurality of plant pathogenic bacteria such as the Botryosphaeria dothidea, the Phytophthora nicotianae, the Fusarium solanum, the Alternaria solanacearum and the like. The Brucella HNIV0701 can hydrolyze organic phosphorus and can be used for soil improvement. The Brucella HNIV0701 has nitrogen fixation capability and has the potential of promoting plant growth.

The invention discloses a primer group, a kit and a method for detecting brucella, and belongs to the technical field of gene detection. The primer group comprises two pairs of specific RPA (recombinase polymerase amplification) primers: a primer pair B1F1 (SEQ ID No.3) and a primer pair B1R1 (SEQ ID No.6) targeting a B1 sequence, and a primer pair B2F1 (SEQ ID No.8) and a primer pair B2R1 (SEQ ID No.11) targeting a B2 sequence. The invention also provides a kit containing the primer group, and a detection method based on the RPA-CRISPR-Cas12a. The invention also provides a kit containing the primer group and a detection method based on the RPA-CRISPR-Cas12a. According to the application, the high efficiency of RPA amplification is combined with the ultrahigh specificity of CRISPR-Cas12a detection, the defects of long time consumption, low sensitivity and easy generation of false positive in the traditional method are overcome, rapid, sensitive and specific detection of Brucella is realized, and the application has important application value in early screening and monitoring of Brucella.

The invention discloses an mRNA-LNPs Brucella vaccine, an expression vector and a preparation method thereof. The mRNA-LNPs Brucella vaccine comprises at least one of mRNA of an outer membrane protein BP26 and mRNA of an outer membrane protein Omp 25. According to the present invention, the antigen sequence is optimized, the prepared mRNA Brucella vaccine can stimulate the body to produce strong immunogenicity, and compared with the Brucella vaccine prepared before the sequence optimization, the antibody titer is significantly improved. A mouse immune experiment research result shows that high-titer IgG, IgG1 and IgG2a can be generated. Th1 type reaction, Th2 type reaction or mixed Th type reaction is successfully induced.

The invention relates to a PCR (Polymerase Chain Reaction) kit and method for identifying brucella pathogens and application. The PCR kit comprises primer pairs and probes for simultaneously detecting brucella BA0711 vaccine strains, M5-9026 vaccine strains, Rev.1 vaccine strains and wild strains. A primer pair for detecting the brucella BA0711 vaccine strain is shown as SEQ ID NO.1-2, and a probe is shown as SEQ ID NO.3; a primer pair for detecting the M5-9026 vaccine strain is shown as SEQ ID NO.4-5, and a probe is shown as SEQ ID NO.6; a primer pair for detecting the Rev.1 vaccine strain is shown as SEQ ID NO.7-8, and a probe is shown as SEQ ID NO.9; a primer pair for detecting positive brucella is shown as SEQ ID NO.10-11, and a probe is shown as SEQ ID NO.12; the kit has the advantages of high sensitivity and strong specificity, and can simultaneously distinguish a plurality of vaccine strains and wild strains.

The invention provides a Brucella immunosuppressive gene BtpB deletion vaccine as well as a preparation method and application thereof, and belongs to the technical field of vaccine strains. The invention provides a suicide plasmid for knocking out a BtpB gene in a bovine brucella A19 vaccine strain and a gene deletion strain prepared on the basis of the suicide plasmid, and the BtpB gene deletion is performed on the brucella A19 strain so as to achieve the purpose of modifying the A19 vaccine. The A19 delta BtpB deletion strain constructed by the invention can reduce damage to host visceral organs, can induce a mouse to generate a high-titer Brucella specific antibody IgG, can better induce the mouse to generate Th1 type cytokines, and can provide better protective efficacy for the mouse than an A19 vaccine strain, so that the A19 delta BtpB deletion strain can be used as a vaccine for the mouse. The A19 delta BtpB deletion strain is expected to become a novel Brucella gene deletion vaccine candidate, and a theoretical basis and a data support are provided for developing a novel Brucella gene deletion vaccine.

The present invention relates to a composite microbial agent and its use in the remediation or management of persistent organic polluted sites. The composite microbial agent comprises a composite microorganism comprising Pseudomonas, Bordetella, Dokshima, and Brucella in a ratio of (0.1-10):(0.1-10):(0.5-1):1. This agent improves the remediation efficiency of persistent organic polluted sites and is particularly suitable for green and efficient remediation of soil and groundwater in sandy soil sites and for pollution source reduction risk management. It also offers advantages such as low cost and ease of operation, thus possessing significant application prospects.

The present invention belongs to the field of biomedicine technology, and specifically relates to the use of a Brucella OMP16 monoclonal antibody in the preparation of a product for inhibiting Brucella, wherein the heavy chain variable region amino acid sequence of the Brucella OMP16 monoclonal antibody is shown in SEQ ID NO.1, and the light chain variable region amino acid sequence is shown in SEQ ID NO.2. Through in vivo and in vitro tests, the present invention verifies the potential of the OMP16 monoclonal antibody as a therapeutic antibody in the treatment of brucellosis.

The invention provides a gntR17 gene deleted strain M5 delta gntR17 as well as a construction method and application thereof, and belongs to the technical field of biology. The M5 delta gntR17 strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation date is July 4, 2024, and the preservation number is CGMCC NO.46061. The M5 delta gntR17 strain is preserved in the China General Microbiological Culture Collection Center (CGMCC). It is found that the gntR17 gene is a related gene affecting the virulence of the brucella, the virulence of the brucella can be weakened by deletion of the gntR17 gene, the safety is improved, the survival ability of the brucella in cells and a mouse body can be remarkably reduced after deletion of the gntR17 gene, and the gntR17 gene has potential application value. Compared with the original brucella M5 strain, the M5 delta gntR17 strain constructed after the gntR17 gene is knocked out has the advantages that the virulence is weakened, the safety is high, the immune protection similar to that of an M5-90 delta 26 vaccine is realized, and the strain can be used as a candidate attenuated live vaccine strain for preventing animal brucellosis.

The invention relates to the technical field of biological detection, and particularly discloses a bovine brucella antibody immunochromatography detection test strip as well as a preparation method and application thereof. The bovine brucella antibody immunochromatography detection test strip provided by the invention comprises a PVC (Polyvinyl Chloride) bottom plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad are arranged on the PVC bottom plate; the combination pad contains a mouse anti-bovine IgG monoclonal antibody marked by quantum dot microspheres; a detection line T and a quality control line C are arranged on the nitrocellulose membrane; the detection line T is coated with a brucella LPS antigen, and the quality control line C is coated with a goat anti-mouse IgG polyclonal antibody. The bovine brucella antibody immunochromatography detection test strip provided by the invention has the advantages of no subjective influence of a detector, simplicity and convenience in operation, high detection sensitivity and specificity and the like.

The invention relates to the field of microorganisms, and in particular relates to a Brucella intermedia 33, a vegetable preservative and application of the Brucella intermedia 33 and the vegetable preservative. The invention provides a strain of Buttiauxella agrestis 33, and the preservation number of the Buttiauxella agrestis 33 is CGMCC (China General Microbiological Culture Collection Center) No.34251. The invention also provides a preparation method of the Buttiauxella agrestis 33. After broccoli is treated by the strain, the postharvest yellowing of the broccoli can be obviously inhibited. Afterwards, the expression of genes related to chlorophyll metabolism pathways and antioxidant enzymes in the broccoli treated by utilizing the Brucella intermedia 33 is detected through real-time fluorescent quantitative reverse transcription PCR, and the result shows that the Brucella intermedia 33 inhibits yellowing of the broccoli after being picked by activating chlorophyll synthesis and the expression of the genes related to the antioxidant enzymes; and the oxidation resistance of the broccoli is improved.

The invention relates to a silicon-based nano material for targeted therapy of brucellosis as well as a preparation method and application of the silicon-based nano material. The invention relates to a preparation method of a silicon-based nano material for targeted therapy of brucellosis. The preparation method comprises the following steps: (1) preparing magnetic mesoporous silica; (2) aminating the magnetic mesoporous silica, and modifying the magnetic mesoporous silica with a responsive material and yeast beta-glucan to obtain modified magnetic mesoporous silica; and (3) carrying out antibiotic loading on the modified magnetic mesoporous silica. According to the silicon-based nano material for targeted therapy of brucellosis as well as the preparation method and the application of the silicon-based nano material, the surface of magnetic macroporous mesoporous silica is modified with yeast beta-glucan capable of targeting M cells and glutathione responsive molecules, and a drug delivery system sensitive to a brucellosis environment is synthesized; the nano-carrier has targeted targeting selectivity for delivering and releasing drugs, the activity, slow release and target cell uptake efficiency of antibiotics are ensured, and the brucellosis treatment is more accurate and efficient.

The invention belongs to but not limited to the technical field of genetic engineering technology, and discloses a construction method and application of a BspE gene deletion strain of Brucella effect protein, the BspE gene deletion strain is constructed by using homologous recombination and SacB reverse screening technology, Brucella abortus A19 vaccine strain liquid is used as a template, PCR amplification is carried out to obtain upstream and downstream homologous arms of BspE gene, and the BspE gene deletion strain is constructed by using the upstream and downstream homologous arms of the BspE gene. The method comprises the following steps: carrying out fusion PCR (Polymerase Chain Reaction) amplification on upstream and downstream homologous arms of a BspE gene subjected to gel recovery, and connecting and transforming an obtained fusion fragment and a pUC19-SacB plasmid to obtain a recombinant plasmid pUC19-delta BspE. The invention relates to a bovine brucella BspE deletion vaccine strain, which is characterized in that a plasmid is obtained, the plasmid is electrically transformed into a bovine brucella A19 competent cell, and the positive transformant is a bovine brucella BspE deletion strain through kanamycin resistance and sucrose pressure screening, PCR (polymerase chain reaction) identification and sequencing, and the deletion vaccine strain improves the levels of antibacterial cytokines and specific brucella antibody IgG, and can be used for preparing the bovine brucella BspE deletion vaccine strain. The Brucella attenuated vaccine strain is a novel Brucella candidate attenuated vaccine strain and has a good market prospect.

The invention belongs to the technical field of biological agents and bioremediation, and particularly relates to a PAHs degrading strain as well as a fungicide and application thereof. The invention provides a strain for degrading PAHs (polycyclic aromatic hydrocarbons), the strain is Brucella anthrapi M1, and the preservation number of the strain is CCTCC (China Center for Type Culture Collection) M 2024922. The strain M1 can grow and breed by taking benzo (a) pyrene (BaP), pyrene or phenol as the unique carbon source and energy, and can quickly degrade PAHs; the strain is cultured in an inorganic salt culture medium with BaP, pyrene and phenol initial concentration of 5 mg / L for 5 days, and the degradation efficiency reaches 81%, 37% and 28% respectively. The bacterial strain is prepared into a microbial inoculum through crosslinking of sodium alginate and calcium chloride, and the degradation efficiencies of the microbial inoculum to BaP, pyrene or phenol respectively reach 46%, 37% and 80%. After the bacterial strain is prepared into a bacterial agent, the BaP degradation efficiency of the bacterial agent can reach 80%. Therefore, the strain and the fungicide thereof have a good application prospect in the bioremediation of PAHs (especially BaP) polluted soil or water.

Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to a vaccine compositions and methods of vaccinating comprising: a Brucella canis comprising one or more attenuating gene knockouts; and a pharmaceutically acceptable vaccine carrier.

The invention relates to the technical field of markers, in particular to application of a biomarker for identifying acute stage and chronic stage of brucellosis. A series of biomarkers related to acute and chronic stages of brucellosis are screened and found, and the biomarkers have obvious difference between acute and chronic brucellosis patients. The biomarkers can realize acute and chronic staging of brucellosis, are high in sensitivity and specificity, and have relatively good diagnosis efficiency. A novel molecular diagnosis tool is provided for acute and chronic staging of brucellosis, the problems that existing serological detection is low in specificity, and clinical staging cannot be accurately judged are solved, and wide application prospects are achieved.

The invention is applicable to the technical field of genetic engineering and biological medicine, and provides construction of a fusion recombinant protein ABT for preventing brucellosis and application of the fusion recombinant protein ABT in preparation of protective vaccines. The fusion recombinant protein ABT is composed of an immunological enhancement antigen and a multi-epitope tandem antigen, wherein the immunological enhancement antigen (named as A) comprises a Brucella ribosome L7 / L12 protein and a PADRE sequence; the multi-epitope tandem antigen is formed by connecting a dominant B cell epitope part (named as B), a dominant Tc cell epitope part and a dominant Th cell epitope part (named as T) in series, wherein the dominant B cell epitope part (named as B) is derived from Brucella SurA, OMP31, BP26 and Trigger factor proteins. The ABT Brucella multi-epitope subunit vaccine prepared by mixing the fusion recombinant protein ABT and an immunologic adjuvant has the characteristics of good purity, high safety and strong immunogenicity, can stimulate an organism to generate a protective antibody, and has long antibody maintenance time.

A diagnostic kit for a confirmatory assay using the indirect ELISA method that measures the levels of anti-Native Hapten antibodies produced during a real infection, thereby preventing large financial losses to livestock farm, by discerning “false positives” that present anti-LPS antibodies due to cross-reactions with enterobacteria and post-vaccinal antibodies for the diagnosis of bovine brucellosis in blood serum and individual milk (per animal) and bulk milk (tank), characterised by using the crude Native Hapten antigen, extracted from B. melitensis 16M strain, with no purification treatment and an effective adherence capacity, which is used to antigenize plates at a known concentration (1 μg per well), where using as reference positive and negative controls subjected to the lyophilisation (freeze drying) method to ensure their preservation, thereby avoiding the contamination and degradation of the antibodies present and ensuring the stability of the optical densities in said controls for a correct results interpretation of an indirect ELISA, are taken as reference. The lyophilisation method for controls that may be used in other diagnostic methods is also presented.

The invention belongs to the technical field of vaccine preparation, and particularly relates to a Brucella recombinant adenovirus based on antigen epitopes of CU / ZN-SOD, BP26 and OMP31 and application of the Brucella recombinant adenovirus, and the nucleotide sequence of the Brucella recombinant adenovirus is shown as SEQ ID NO: 1. The recombinant adenovirus provided by the invention can induce high-level cellular immune response level and humoral immune response level, which are biased to Th1 type immune response, and in addition, the recombinant adenovirus is high in immune safety.

The invention discloses a salt-tolerant efficient denitrification strain and application thereof, and belongs to the technical field of microorganisms. The invention provides a salt-tolerant high-efficiency denitrification (Brucella anthropi N2-2) strain, and the preservation number of the strain is CCTCC (China Center for Type Culture Collection) NO: M 20241934. The salt-tolerant efficient denitrification strain (Brucella anthropi N2-2) provided by the invention has the best denitrification effect when the salinity is 0-3 wt%, the inoculum size is 2% (v / v) and the pH value is 7.5-8.5. According to the present invention, the thallus preparation containing the strain (Brucella anthropi N2-2) is put into the culture pond, such that the contents of ammonia nitrogen, nitrite nitrogen, organic nitrogen and nitrate in the water body can be effectively reduced, the pH value of the water body can be regulated to the normal range so as to maintain the relative stability of the culture water body;

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

Provided herein are methods and compositions for the detection of Brucella antigen, and more particularly, to a vaccine or immunogenic composition comprising: Brucella strain from which at least a portion of the immunogenic protein DUF883 has been deleted provided in an amount sufficient to trigger an immune response against the immunogenic protein; and a pharmaceutically acceptable vaccine carrier.

The invention discloses a method for carrying out protein chip detection on brucellosis, and relates to the technical field of brucellosis detection. The preparation method comprises the following steps: spotting a Brucella synergistic composite antigen for multi-index joint detection on a pretreated solid-phase carrier, drying and washing; then adding a sealing agent for sealing, and washing to obtain a protein chip; then collecting an initial sample, diluting and centrifuging, and taking supernate; adding the supernate to a protein chip site, oscillating, incubating, washing, adding a secondary antibody, further incubating and washing; and finally, reading the signal by using a fluorescence scanner, deducting the background, and interpreting the positive and negative properties. The method is wide in detection range, strong in specificity and high in sensitivity, and has a very wide application prospect.

The application discloses a serological method for identifying Brucella A19-DeltaVirB12 vaccine immunized animals and infected animals, and belongs to the technical field of veterinary vaccine detection, comprising the step of identifying the antibodies of the serum by using the NH-AGID method. The method helps to perfect the animal Brucella A19-DeltaVirB12 vaccine prevention and control technical system, makes up for the short board that the A19-DeltaVirB12 vaccine immunized animals cannot be identified, and provides technical support for realizing the precise prevention and control of bovine brucellosis. The application of the method will accelerate the application of the Brucella A19-DeltaVirB12 vaccine to replace the traditional A19 vaccine, and opens a new milestone for the prevention and control of Brucella.

The invention belongs to the technical field of animal epidemic disease pathogen detection, and particularly relates to a primer composition and a kit for identifying a Brucella universal type and a vaccine strain, the primer composition comprises primer pairs and probes for identifying the Brucella universal type, a pig breed S2 vaccine strain and a cattle breed A19 vaccine strain; the primer pair for identifying the universal type of Brucella is shown as SEQ ID NO.1-2, and the probe is shown as SEQ ID NO.3; a primer pair for identifying the pig breed S2 vaccine strain is SEQ ID NO.4-5, and a probe is SEQ ID NO.6; the primer pair for identifying the bovine species A19 vaccine strain is SEQ ID NO.7-8, and the probe is SEQ ID NO.9; the specificity and the sensitivity are good.

In one aspect, an EID button tag is provided herein for tagging and identifying cattle as being inoculated against brucellosis, the EID button tag including: a shell having a central opening; a transponder located in the shell; a male punch having a disc-shaped punch body and a stem extending distally therefrom, the stem having a head configured for irreversible insertion into the central opening, wherein a mounting opening is formed through the punch body with a mounting channel extending distally from the mounting opening and coaxially along the stem; and, a vaccination identification button having a disc-shaped visual identification body and a mounting stem extending distally therefrom, wherein the mounting stem is configured for irreversible insertion into the mounting channel. The punch body and the visual identification body are primarily tinted with different colors to provide visual identification of a head of cattle being inoculated against brucellosis.

The embodiment of the present invention provides a Mongolian medicine and Mongolian medicine preparation for treating brucellosis. The Mongolian medicine is composed of the following raw materials in parts by weight: 3-7 parts of long-haired silver anemone, 3-6 parts of terminalia chebula, 3-6 parts of donkey ear wind chrysanthemum, 2-4 parts of multi-leaf thorn beans, 2-4 parts of purple flower aconite, 2-4 parts of horn fennel, 2-4 parts of aconite leaves, 2-4 parts of liquorice, 2-4 parts of coptis root, 2-4 parts of scutellaria, 2-4 parts of borneol, 2-4 parts of sophora flavescens, 2-4 parts of cyrtomium, 2-4 parts of calamus, 2-4 parts of processed aconite, 2-4 parts of bamboo yellow, 2-4 parts of purple ginseng, 2-4 parts of black borneol, 2-4 parts of scutellaria baicalensis, 2-4 parts of musk. The Mongolian medicine provided by the present invention is a traditional prescription, and it can be seen from a large number of clinical trials that the Mongolian medicine of the present invention has a definite curative effect on brucellosis.

The utility model provides a detection card for Brucella antibody detection, which comprises a shell, the shell is internally provided with a detection card, one side of the top end of the shell is provided with an opening, the detection card is provided with a detection part, the detection part directly faces the opening, the detection part comprises three detection areas, and the three detection areas are arranged in the shell. The three detection areas are sequentially provided with a first detection line, a second detection line and a control line from front to back. According to the present invention, by arranging the detection card, when the Brucella antibody is detected, if the first detection line and the second detection line of the detection part simultaneously appear the obvious lines, the Brucella antibody is determined to be positive, such that the detection result is more accurate compared with the traditional one detection line.